A Medical Device Daily

Research & Diagnostic Antibodies (R&D Antibodies; Las Vegas) reported that it has received a notification stating that the European Patent Office intends to grant a patent for its monoclonal antibody-based immunoassays and apparatuses for measuring inducible nitric oxide synthase (iNOS) as a plasma biomarker for the early detection of the sepsis pathology.

This notification is equivalent to a "Notice of Allowance" by the U.S. Patent Office. European patent application 01959345 covers very broadly the use of R&D Antibodies' immunoassays, kits, and apparatuses for the detection of plasma iNOS as a biomarker for the prognosis and diagnosis of Systemic Inflammatory Response Syndrome (SIRS) that will deteriorate into sepsis.

Plasma iNOS is the foundation of R&D Antibodies' SIRS prognosis and monitoring tests that reveal very early the progression from SIRS into sepsis and indicate the course of this life-threatening pathology. R&D Antibodies has conducted three clinical studies involving more than 295 ICU patients using tests based upon its patented anti-iNOS monoclonal antibodies.

In other patent news, CardioNet (Conshohocken, Pennsylvania) reported that the USPTO has granted patent number 7,587,237 to CardioNet. The patent includes certain systems and techniques utilized by the company's Mobile Cardiac Outpatient Telemetry (MCOT) system that automatically processes complex physiological information to make it useful for clinical decisions.

The issued patent abstract states: Systems and techniques for managing biological signals. In one implementation, a method includes receiving a cardiac biological signal that includes information describing events, determining a merit of each event based on one or more of a severity of a cardiac condition associated with the event and a quality of the event, and handling a subset of the events that meet a merit criterion. The subset can be handled for medical purposes.